Anti-inflammatory effects of epoxyeicosatrienoic acids.
ABSTRACT Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs). EETs have been shown to have a diverse range of effects on the vasculature including relaxation of vascular tone, cellular proliferation, and angiogenesis as well as the migration of smooth muscle cells. This paper will highlight the growing evidence that EETs also mediate a number of anti-inflammatory effects in the cardiovascular system. In particular, numerous studies have demonstrated that potentiation of EET activity using different methods can inhibit inflammatory gene expression and signalling pathways in endothelial cells and monocytes and in models of cardiovascular diseases. The mechanisms by which EETs mediate their effects are largely unknown but may include direct binding to peroxisome proliferator-activated receptors (PPARs), G-protein coupled receptors (GPCRs), or transient receptor potential (TRP) channels, which initiate anti-inflammatory signalling cascades.
[show abstract] [hide abstract]
ABSTRACT: In response to infections or tissue injury, circulating leucocytes adhere to and migrate from the vessel lumen to interstitial inflammatory sites to combat invading pathogens. However, these defensive actions may also cause host tissue injury and microvascular dysfunction through oxidative bursts or enzyme release. For decades, the interaction between leucocytes and microvessel walls has been considered as a critical event leading to organ dysfunction. Extensive investigations have therefore focused on blocking specific adhesive ligands to prevent tissue injury. However, anti-adhesion therapies have shown limited success in preventing vascular dysfunction in clinical trials. Numerous studies have demonstrated temporal and spatial dissociations of leucocyte adhesion and/or emigration from permeability increases. The mechanisms that initiate the adhesion cascade have been found to be distinct from those that trigger the leucocyte oxidative burst responsible for increasing microvessel permeability. Recent studies demonstrated that endothelial activation by inflammatory mediators is critical for initiating platelet adhesion and platelet-dependent leucocyte recruitment resulting in augmented increases in microvessel permeability. These new developments suggest that targeting endothelial activation via directly enhancing endothelial barrier function might be a more efficient strategy than focusing on anti-adhesion or platelet/leucocyte depletion to prevent vascular damage during inflammation. Owing to space limitations and the wide range of studies in the field, this article will not serve as a comprehensive review. Instead, it will highlight the emerging evidence of adhesion-uncoupled permeability changes and establish a basis for re-evaluating the coupled relationship between leucocyte/platelet activation and microvessel permeability to achieve a better understanding of permeability regulation during inflammation.Cardiovascular research 07/2010; 87(2):281-90. · 5.80 Impact Factor
[show abstract] [hide abstract]
ABSTRACT: A fundamental feature of any immune response is the movement of leucocytes from one site in the body to another to provide effector functions. Therefore, elucidating the molecular mechanisms underlying the migration of leucocytes from the blood to tissues is critical to our understanding of immune function during inflammation. The classic steps of leucocyte trafficking involve leucocyte tethering and rolling on vessel walls of the vasculature, followed by firm adhesion to the endothelium. Recent evidence suggests that upon adhering, leucocytes crawl within the vessels before transmigrating across vessel walls and crawling into targeted tissues. The directed nature of the crawling events is orchestrated by a complex array of soluble factors and molecular regulators in combination with the local intravascular and extracellular environment. In fact, this process is known as chemotaxis and orientates cell movement in relation to the ligand gradient. Several signalling pathways have been proposed to be involved in this gradient-sensing and amplification process, but the best studied, discussed in detail here, is the phosphatidylinositol 3-kinase pathway. Substantial progress has been made in understanding how cells roll and adhere in blood vessels; however, how cells crawl in blood vessels, emigrate, and then crawl in tissues has received much less attention. Therefore, the focus of this review is to provide recent insights into molecular mechanisms and cellular processes that mediate leucocyte crawling in blood vessels and tissues during the inflammatory response.Cardiovascular research 05/2010; 86(2):183-91. · 5.80 Impact Factor
[show abstract] [hide abstract]
ABSTRACT: The cytokines are multipotent mediators of inflammation and immunity that can affect key functions of vascular wall cells. Growing evidence suggests that cytokines participate as autocrine or paracrine mediators in atherogenesis, as cells in lesions can both produce and respond to these mediators. The functions of vascular wall cells regulated by cytokines may influence lesion initiation, progression, or complication. For example, cytokines can regulate the expression of adhesion molecules crucial to the recruitment of leukocytes to lesions, including vascular cell adhesion molecule-1 (VCAM-1). Cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) can regulate the production of monocyte chemoattractant protein-1 (MCP-1), a potential signal for directed migration of monocytes into the intima. Cytokines can also regulate genes that encode other growth factors and cytokines themselves. TNF-alpha can induce IL-1 mRNA in human endothelial (EC) and smooth-muscle cells (SMC). IL-1 and TNF-alpha can augment the production by vascular cells of macrophage-colony stimulating factor (M-CSF), which may promote growth and activation of mononuclear phagocytes. Cytokines can exert both pro-and antiatherogenic actions. Activated T cells in human atheroma may secrete the lymphokine IFN-gamma, an inhibitor of SMC proliferation. Cytokines influence vasomotor tone in arteries, e.g., by inducing a form of nitric oxide synthase, the enzyme that synthesizes the vasodilatory nitric oxide radical. The cytokines also modulate endothelial functions that govern the formation and stability of blood thrombi. Finally, in the late stages of the disease, matrix metalloproteinases derived from macrophages or smooth-muscle cells themselves may contribute to weakening of the fibrous cap in the vulnerable shoulder area, promoting plaque rupture and occlusive thrombosis, culminating in the dramatic clinical manifestations of atherosclerosis, including myocardial infarction and stroke. Thus, cytokines can influence multiple aspects of atherogenesis and provide new and interesting targets for therapeutic intervention.Journal of Cardiovascular Pharmacology 02/1995; 25 Suppl 2:S9-12. · 2.29 Impact Factor
Hindawi Publishing Corporation
International Journal of Vascular Medicine
Volume 2012, Article ID 605101, 7 pages
Anti-Inflammatory Effectsof EpoxyeicosatrienoicAcids
Scott J. Thomson, AraAskari,andDavidBishop-Bailey
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
Correspondence should be addressed to Scott J. Thomson, firstname.lastname@example.org
Received 30 May 2012; Accepted 20 June 2012
Academic Editor: Ken-ichi Aihara
Copyright © 2012 Scott J. Thomson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450
(CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their
corresponding dihydroxyeicosatrienoic acids (DHETs). EETs have been shown to have a diverse range of effects on the vasculature
including relaxation of vascular tone, cellular proliferation, and angiogenesis as well as the migration of smooth muscle cells. This
paper will highlight the growing evidence that EETs also mediate a number of anti-inflammatory effects in the cardiovascular
system. In particular, numerous studies have demonstrated that potentiation of EET activity using different methods can inhibit
inflammatory gene expression and signalling pathways in endothelial cells and monocytes and in models of cardiovascular
diseases. The mechanisms by which EETs mediate their effects are largely unknown but may include direct binding to peroxisome
proliferator-activated receptors (PPARs), G-protein coupled receptors (GPCRs), or transient receptor potential (TRP) channels,
which initiate anti-inflammatory signalling cascades.
Cardiovascular diseases such as atherosclerosis have a strong
inflammatory component. Inflammation in the vascular
wall may be initiated by endothelial dysfunction and
the accumulation of toxic oxidised circulating lipids .
Inflammatory mediators such as TNFα and IL-1β secreted,
which induces the upregulation of cell adhesion molecules,
facilitates leukocyte recruitment in to the vascular wall [2, 3]
and stimulates vascular smooth muscle cell migration and
proliferation . Circulating monocytes not only respond
to inflammatory stimuli by producing large amounts of
activation of lymphocytes and adaptive immunity. The hall-
are monocyte/macrophage rich and highly inflammatory.
Inflammatory responses are normally promptly termi-
nated since excessive or prolonged inflammation can lead
to chronic pathological conditions such as cardiovascular
diseases, Crohn’s disease, rheumatoid arthritis, or cancer.
Although there have been many new treatments recently
developed to combat inflammatory diseases, some of these
treatments are either very expensive and/or not effective
in subsets of patients. Therefore, it is important to con-
tinue to investigate mechanisms that regulate inflammatory
responses as they may open up novel therapeutic targets.
There is a growing list of evidence that the epoxygenase
pathway of arachidonic acid metabolism, which generates
epoxyeicosatrienoic acids (EETs), exerts anti-inflammatory
effects that may be harnessed to treat disease. This paper
will summarise that evidence and highlight outstanding
questions that remain to be answered.
2.Overview of the Epoxygenase Pathway of
Arachidonic acid is an omega-6 polyunsaturated long chain
fatty acid that contains 20 carbon atoms and four cis-
double bonds and possesses a carboxyl group and a methyl
group at respective ends of the molecule. The double bonds
are located between carbons 5-6, 8-9, 11-12, and 14-15
relative to the carboxyl group. Therefore, its chemical name
is all-cis-5,8,11,14-eicosatetraenoic acid and its lipid name
2International Journal of Vascular Medicine
is 20:4 (n-6). The cis-configuration of the four double
bonds causes the arachidonic acid backbone to significantly
bend. In contrast, double bonds in the trans-configuration
or saturated arachidonic acid result in structurally unbent or
Experiments performed more than 30 years ago showed
that incubations of radio-labelled arachidonic acid with
microsomal preparations derived from a variety of tissues
including liver [5, 6], kidney , hypothalamus , and
anterior pituitary  resulted in the formation of EETs.
This “epoxygenase” reaction required cytochrome p450
(CYP) enzymes and utilised NADPH and oxygen in a 1:1
stoichiometric ratio . One atom of molecular oxygen
is incorporated into one of the four double bonds of
arachidonic acid retaining the cis-geometry and yielding
four potential EETs, that is, 5,6-EET, 8,9-EET, 11,12-EET,
or 14,15-EET, respectively. Furthermore, each EET can be
present in either the S/R or R/S stereoconfiguration, thus
eight potential EETs can be formed.
2.1. Epoxygenation of Arachidonic Acid Performed by Spe-
cific CYPs. CYP enzymes catalyze the oxidation of organic
substances, as well as xenobiotics. Altogether, 57 putative
CYP genes have been identified in man (by comparison
mice have 103 and rat 89 CYP, resp.) that are divided into
15 subfamilies . Attempts have been made to classify
human CYP genes by substrate; however, a more systematic
nomenclature is generally used since the true physiological
roles of many of these genes are still unknown . To
date, at least 12 human CYP genes have been reported to
possess epoxygenase activity, although most studies have
been focussed on the CYP2C and CYP2J families, which are
considered the major epoxygenase enzymes.
2.2. CYP2C. One of the earliest studies using recombinant
human CYP compared the metabolic profiles of the CYP2C8
and CYP2C9 enzymes , which are 77% identical at the
amino acid level. Despite their high similarity, CYP2C8 and
CYP2C9 exhibit both regio- and stereoselective differences
in their epoxygenation of arachidonic acid. For instance,
CYP2C8 produced only 14,15-EET and 11,12-EET at a
1.25:1 ratio, which represented 68% of the total metabolites
measured. By contrast, CYP2C9 produced 14,15-EET 11,12-
EET and 8,9-EET at a ratio of 2.3:1:0.5, which represented
69% of total metabolites. Furthermore, with respect to stere-
oselectivity, CYP2C8 was 81% selective for the 11(R),12(S)-
EET configuration, whereas CYP2C9 was 70% selective for
also carry out other reactions including allylic hydroxylation
on arachidonic acid and other fatty acids.
2.3. CYP2J2. Epoxygenase activity of human CYP2J2 was
first demonstrated by the Zeldin lab, who initially cloned
and characterised the gene . Recombinant CYP2J2
metabolised arachidonic acid to all four potential epoxy-
genase products, with 14,15-EET being the predominant
in the heart, and EETs were produced in similar proportions
as recombinant CYP2J2 suggesting that CYP2J2 played a
major role in EET generation in the heart in vivo .
CYP2J2 expression is also seen in kidney, liver and muscle
tissues , and, to a lesser extent, in the gut .
2.4. Other CYPs. A comprehensive comparison study by
Rifkind and colleagues examined the epoxygenase activity of
a panel of 10 CYP proteins by overexpressing them in HepG2
cells and measuring metabolic products. CYP 2C8, 2C9,
contrast, CYP2D6 was inactive, while CYPs 2A6, 3A3, 3A4,
and 3A5 had minimal epoxygenase activity . CYP3A4
has also been shown to make the epoxygenase products 8,9-
cancer cell lines . Other CYPs that have been shown
to possess epoxygenase activity include CYP1A, CYP2B1
and CYP2B2  and CYP2B12 , CYP2C8, CYP2C9,
CYP2D18 , CYP2N1 and CYP2N2 , and rat CYP4A2
and 4A3 . The full extent of the epoxygenase activity
of these enzymes and the physiological consequences of any
activity is, however, poorly understood.
Once formed, EETs are unstable because they are rapidly
EETs into dihydroxyeicosatrienoic acid (DHETs), catalysed
by soluble epoxide hydrolase (sEH) . DHETs are gen-
erally considered to be less active; however, they have been
shown to exert vasodilatory effects on coronary arteries .
DHETS are far more polar than their corresponding EETs
and quickly diffuse out of tissues as the 1, diols or conjugates
of them. Other pathways of EET metabolism include chain
elongation, β-oxidation, and ω-oxidation . 5,6 EET and
8,9 EET are substrates for COX enzymes  and can also be
incorporated into membrane phospholipids. DHETs have a
lower binding affinity for phospholipids which may account
for its relatively increased plasma levels .
Recently, the damaging cardiovascular risk factor homo-
cysteine has been shown to upregulate sEH in endothelial
cells and promote a proinflammatory environment . In
contrast, elevating the levels of endogenous CYP products by
hydrolase (sEH-1) has been shown to reduce neointima for-
mation , atherosclerosis and abdominal aortic aneurysm
development, dyslipidaemia in hyperlipidaemic mice ,
and reduce hypertension  and diabetes  in different
mouse models. A number of sEH inhibitors have now been
developed and are moving towards clinical trials for a variety
of disorders related to cardiovascular disease.
CYP2C mediated generation of 11,12 EET has also been
documented in porcine coronary arteries , and CYP2C
enzymes have been found expressed in endothelial cells ,
International Journal of Vascular Medicine3
and in primary human monocytes and M1 (CYP2C8) and
M2 macrophages (CYP2C8 and CYP2C9) .
CYP2J2 immunoreactivity is seen in the endothelial and
well as in the human monocytic cell lines THP-1 and U937,
primary monocytes and M1 and M2 macrophages ,
and the endothelial cell line EA hy.926s . Interestingly,
neither CYP2J2 nor CYP2C8 mRNA expression was detected
in human polymorphonuclear cells . More recently, the
increased risk of coronary artery disease was shown to be
associated with a polymorphism in the promoter of CYP2J2
gene in some populations, which decreases the expression of
the enzyme .
EETs have been shown to exert multiple biological effects
on the vasculature including proproliferation and angio-
genic effects . EETs have also been hypothesized as
endothelium-derived hyperpolarizing factors, as they hyper-
polarize and relax vascular smooth muscle cells by activat-
ing calcium-activated potassium channels . However,
a number of the anti-inflammatory activities of EETs on
inflammatory cells, as discussed below, appear independent
of any cellular hyperpolarisation .
5.1. Endothelial Cells. Overexpression of CYP2J2 in human
VCAM-1  and VCAM-1 promoter activity in reporter
assays . Treatment with the epoxygenase inhibitor
SKF525A reversed the effects of CYP2J2 overexpression on
VCAM-1 promoter activity . Exogenous EETs also exert
EETs can have different selectivities. In human endothelial
cells, 11,12-EET significantly inhibited VCAM-1 expression
in response to TNFα, IL-1α, or LPS. By contrast, 14,15-EET
had negligible effect, while 5,6-EET, 8,9-EET, and 11,12-
DHET all inhibited to varying degrees but to a lesser extent
than 11,12-EET. 11,12-EET also inhibited TNFα-induced
E-selectin and ICAM-1 expression . Mice engineered
to overexpress the human epoxygenase genes CYP2J2 or
CYP2C8, respectively, were generated to investigate their
roles in endothelial cells. Primary pulmonary endothelial
cells derived from these mice showed reduced levels of LPS-
induced adhesion molecule and chemokine gene expression.
Furthermore, these anti-inflammatory effects were inhibited
by treatment with the epoxygenase inhibitor MS-PPOH and
a putative EET receptor antagonist 14,15-EEZE .
has also been shown to antagonise inflammatory signals in
monocytic cells. Phorbol ester treatment of THP-1 led to
a 4-fold increase in CYP2J2 expression between 3–7 days
after stimulation, suggesting that endogenous expression
of CYP2J2 may regulate inflammatory responses in these
cells . Addition of 8,9-EET or 11,12-EET inhibited
basal TNF secretion from THP1 cells by about 90% and
40%, respectively . Similarly, the epoxygenase inhibitor
SKF525A led to a concentration-dependent superinduction
of LPS-induced PGE2in rat monocytes and COX-2 in mouse
and human monocytes . Consistent with these find-
ings, exogenous 11,12-EET dose dependently inhibited LPS-
induced PGE2 and attenuated SKF-mediated superinduc-
tion. 11,12-EET also inhibited LPS-induced COX-2 activity
and expression . EETs can, therefore, both compete with
arachidonic acid for the binding site in COX enzymes as
well as inhibit the inflammation induced induction of COX-
2 expression. A study found that EETs were detected in
human peritoneal macrophages under basal conditions, but
not following zymosan treatment, which caused a shift to
prostaglandin synthesis .
5.3. Leukocyte Endothelial Cell Interactions. Several studies
have demonstrated that EETs can regulate functional inter-
action between leukocytes and endothelial cells. Treatment
of endothelial cells with 14,15-EET significantly enhanced
attachment of the monocytic cell line U937 . Pretreat-
ment of endothelial cells with EETs alone or in combi-
nation with PMA had negligible effects on adherence of
PMNs. However, cotreatment of EETs and PMA led to a
concentration-dependent decrease in adherence of PMNs
when cocultured with endothelial cells . 11,12-EET, but
cells in an ex vivo model. Mice were treated with TNFα
and carotid arteries were removed and incubated with U937
to that of treatment with a blocking VCAM-1 antibody
. PBMCs derived from mice systemically overexpressing
human CYP2J2 via in vivo gene delivery were significantly
5.4. In Vivo Models. There have been conflicting reports
on the effects of EETs in acute models of inflammation in
vivo. Rats injected with TNFα showed elevated plasma levels
of adhesion molecules and inflammatory cytokines, and
decreased levels of the anti-inflammatory mediator IL-10.
However, these effects were significantly reduced by systemic
overexpression of human CYP2J2 , suggesting that EETs
act as anti-inflammatory mediators. Similarly, TNFα-treated
human bronchi also showed reduced inflammation when
treated with 14,15-EET . LPS responses of wild-type
mice have also been compared to sEH−/− null mice or mice
that had endothelial-specific overexpression of the human
CYP2J2 or CYP2C8. All three genetically modified mice
had reduced levels of inflammatory gene expression and
neutrophil recruitment in the lung following LPS injection.
Moreover, these effects correlated with decreased activation
of the key transcription factor NF-κB . By contrast,
another study found that to sEH−/− null mice were not
protected from LPS-induced inflammatory gene expression
or neutrophil recruitment in the liver, and that treatment
with the sEH inhibitor AUDA also had minimal effect liver
4International Journal of Vascular Medicine
or that liver is more susceptible to endotoxin shock.
6.1. NF-κB Inhibition. The mechanisms by which EETs
mediate their anti-inflammatory effects remain ill-defined,
but there are several reports that they can inhibit activation
of NF-κB, a key transcription factor for inflammatory gene
induction. In mammals NF-κB comprises five subunits, with
the RelA (p65) subunit being expressed in most cell types.
Under basal conditions, NF-κB dimers are localised in the
cytoplasm due to interactions with IκB (inhibitor of NF-
κB) proteins. Signalling cascades induced by inflammatory
descend on the IKK (inhibitor of NF-κB kinase) complex,
which phosphorylates IκB. This tags IκB for subsequent
turn, facilitates NF-κB nuclear translocation where it binds
to its cognate binding elements to activate transcription
11,12-EET inhibits NF-κB reporter activity in both
HEK293 cells  and human endothelial cells  fol-
lowing stimulation. Furthermore, 11,12-EET also inhibited
TNFα-induced RelA nuclear translocation, IκBα degrada-
tion, and IKKα activity, respectively , indicating that
EET-mediated inhibition of NF-κB occurs upstream of IKK.
Interestingly, 14,15-EET was also shown to inhibit the
TNFα-induced degradation of IκBα in primary human lung
tissue  but had no effect on NF-κB reporter activity
in HEK293s, suggesting that 14,15-EET may act in a cell
type-specific manner. Similarly, 8,9-EET and 11,12-EET
inhibited NF-κB reporter gene activity in HEK293 cells .
In contrast to CYP2J2, CYP2C9 increased NF-κB activity
in human vascular endothelium via superoxide generation,
potentially giving this CYP a proinflammatory profile .
6.2. STAT3. EETs can also activate STAT3 in human breast
cancer cell lines, with 14,15-EET promoting STAT3 tyrosine-
705 phosphorylation and nuclear translocation . Acti-
vation of STAT3 was shown to be dependent on cell
proliferation, which led the authors to conclude that 14,15-
EET may be involved in an autocrine/paracrine pathway
driving cell growth. Interestingly, the anti-inflammatory
effects of IL-10 in macrophages are also dependent on STAT3
tyrosine-705 phosphorylation . Taken together, these
results suggest that the anti-inflammatory effects of EETs
may be mediated by activation of STAT3, in addition to the
inhibition of NF-κB.
6.3. EETs as PPAR Agonists. PPARs are a subfamily of the
nuclear receptor superfamily that comprises three ligand-
activated transcription factors: PPARα (NR1C1), PPARβ/δ
(NR1C2), and PPARγ (NR1C3). Upon ligand binding, they
form heterodimers with the retinoid X receptor and bind to
specific response elements in gene promoters to upregulate
gene transcription . PPARs have been shown to regulate
diverse physiological processes such as fatty acid and glucose
metabolism, angiogenesis, and cellular proliferation and
differentiation, in addition to inflammation. PPAR ligands
include a variety of fatty acids, and there has been recent
evidence that metabolites of the epoxygenase pathway can
activate PPAR receptors.
The omega-alcohol of 14,15-EET, 20,14,15-HEET, or a
1:4 mixture of the omega-alcohols of 8,9- and 11,12-EETs
activated human and mouse PPARα in transient transfection
assays, suggesting a role for them as endogenous ligands
for these orphan nuclear receptors . Overexpression of
human CYP2J2 in HEK293 cells resulted in a synergistic
activation of PPARα, -β/δ and, -γ reporter gene activity.
8,9-EET and 11,12-EET, but not 14,15-EET, (in contrast to
its hydroxy metabolite 20,14,15-HEET) were able to induce
PPARα reporter activity . Furthermore, IL-1β-induced
NF-κB reporter activity and COX-2 mRNA induction in
HEK293 cells was significantly inhibited cells expressing of
CYP2J2 and PPARα.
Competition and direct binding assays subsequently
revealed that EETs bind to the ligand-binding domain of
PPARγ with K(d) in the μM range. In the presence of the
sEH inhibitor AUDA, EETs increased PPARγ transcription
activity in endothelial cells and 3T3-L1 preadipocytes. In
endothelial cells, AUDA enhanced, but overexpression of
sEH reduced laminar flow-induced PPARγ activity, EET
generation, and the inhibition of VCAM-1 expression .
PPARs, therefore, represent a viable receptor target for the
anti-inflammatory effects of EETs. However, it should be
noted that AUDA may exert multiple effects in addition to
sEH inhibition. It has been shown to act both as a PPAR
agonist  and a EET mimetic ; therefore, results using
AUDA should be cautiously interpreted.
6.4. GPCRs. For some time it has been suggested that EETs
might mediate many of their effects via binding to a putative
EET produced a 0.5- to 10-fold increase in the activity of the
KCa channels in smooth muscle cells derived from bovine
coronary arteries, which was dependent on the presence of
GTP . Furthermore, blocking antibodies against GSα,
but not Gβγ or anti-Giα, were able to inhibit the activation
induced by 11,12-EET . Using radio-ligand binding,
14,15-EET has been shown to have a high affinity for a
receptor expressed on guinea pig-derived mononuclear cells,
which was purported to be a G-protein coupled receptor
that stimulated cAMP production . This putative GPCR-
cAMP pathway remains elusive but may represent a novel
anti-inflammatory pathway by which EETs act.
6.5. TRPV1 and EETs. TRPV4 is a cation channel of the
“transient receptor potential” (TRP) family that functions
as a Ca2+entry channel, that is expressed in smooth muscle
cells, endothelial cells, as well as in perivascular nerves.
CYP-dependent generation of 5,6-EET can activate TRPV4
in murine endothelial cells and is a possible contributing
mechanism to the hyperpolarising effects of EETs .
Additionally, 11,12-EET can activate TRPV4 channels in
smooth muscle cells from rat cerebral arteries , and 5,6-
EET and 8,9-EET can activate TRPV4 in human endothelial
International Journal of Vascular Medicine5
cells . Although activated by EETs, there is little evidence
that activation of TRPV4 is anti-inflammatory, though it
does lead to vasodilation via nitric oxide, prostacyclin,
and intermediate/small conductance K+ channel-dependent
pathways, and in vascular smooth muscle, large conductance
K+ channel activation, and hyperpolarization .
More than 100 metabolites derived from arachidonic acid
have been described, with the best characterised com-
ing from the COX and LOX pathways which generate
prostanoids and leukotrienes, respectively . Knowledge
of these pathways has led to several important therapeutic
breakthroughs such as COX inhibitors which are used to
treat pain and inflammation and leukotriene antagonists
that have been used to treat asthma. By contrast, much less
is known about the epoxygenase pathway of arachidonic
acid metabolism, although as outlined in this paper, EETs
can exert a number of cardio-protective anti-inflammatory
effects on vascular cells such as endothelial cells and
monocytes. These include inhibition of proinflammatory
mediators and cell adhesion molecules. Indeed, a recent
study has measured epoxygenase products in atherosclerotic
patients . Compared to healthy volunteers, both obese
and nonobese CAD patients had significantly higher plasma
EETs , suggesting that this is a compensation mechanism
to protect against ongoing vascular inflammation.
Although elevating epoxygenase products via sEH inhi-
bition have been shown to be beneficial in a wide variety
of animal models of cardiovascular disease, the mecha-
nisms through which these effects are mediated are still
largely unknown, although NF-κB and STAT3 have both
been implicated. However, several fundamental question
regarding the role of EETs in vascular inflammation remain
unanswered. Firstly, it is clear that CYP epoxygenases can act
on substrates other than arachidonic acid, such as cardio-
protective fish oils. Eicosapentaenoic acid for example is an
omega-3 long chain fatty acid that differs from arachidonic
acid by the addition of one extra double bond at the 17-
18 carbon position. Epoxygenation of eicosapentaenoic acid
by CYP enzymes generates 17,18-epoxyeicosatrienoic acid,
which has a hyperpolarising effect on bronchial smooth
muscle cells in vitro and in vivo . Similarly, linoleic
acid, which is the major dietary fat, can be epoxygenated
by CYP enzymes resulting in potent metabolites which
are probably proinflammatory in nature. However, little is
known regarding the function of many of these alternative
during inflammation. Secondly, the full range of epoxy-
genase activity by CYP enzymes in healthy and diseased
physiological settings is still not completely understood and
remains a significant barrier to progress in the field. Thirdly,
and probably most importantly, definitive identification of
a specific receptor that mediates the activities of EETs
is essential to fully understand the epoxygenase pathway,
and will help to elucidate new therapies for cardiovascular
diseases in the future.
This work was supported by the British Heart Foundation
 G. Leonarduzzi, P. Gamba, S. Gargiulo, F. Biasi, and G. Poli,
“Inflammation-related gene expression by lipid oxidation-
derived products in the progression of atherosclerosis,” Free
Radical Biology and Medicine, vol. 52, no. 1, pp. 19–34.
 P. He, “Leucocyte/endothelium interactions and microves-
sel permeability: coupled or uncoupled?” Cardiovascular
Research, vol. 87, no. 2, pp. 281–290, 2010.
 C. H. Y. Wong, B. Heit, and P. Kubes, “Molecular regulators
Research, vol. 86, no. 2, pp. 183–191, 2010.
 P.Libby,G.Sukhova,R.T.Lee,andZ.S.Galis,“Cytokines reg-
ulate vascular functions related to stability of the atheroscle-
rotic plaque,” Journal of Cardiovascular Pharmacology, vol. 25,
supplement 2, pp. S9–S12, 1995.
cytochrome P-450 and the oxidative metabolism of arachi-
donic acid,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 78, no. 9, pp. 5362–5366,
 E. H. Oliw and J. A. Oates, “Oxygenation of arachidonic
acid by hepatic microsomes of the rabbit; mechanism of
biosynthesis of two vicinal dihydroxyeicosatrienoic acids,”
Biochimica et Biophysica Acta, vol. 666, no. 3, pp. 327–340,
 E. H. Oliw and P. Moldeus, “Metabolism of arachidonic acid
by isolated rat hepatocytes, renal cells and by some rabbit
tissues. Detection of vicinal diols by mass fragmentography,”
Biochimica et Biophysica Acta, vol. 721, no. 2, pp. 135–143,
 J. Capdevila, N. Chacos, and J. R. Falck, “Novel hypothalamic
 J. Capdevila, G. D. Snijder, and J. R. Falck, “Epoxygenation
of arachidonic acid by rat anterior pituitary microsomal
fractions,” FEBS Letters, vol. 178, no. 2, pp. 319–322, 1984.
 D. R. Nelson, D. C. Zeldin, S. M. G. Hoffman, L. J. Maltais, H.
(CYP) genes from the mouse and human genomes, including
nomenclature recommendations for genes, pseudogenes and
alternative-splice variants,” Pharmacogenetics, vol. 14, no. 1,
pp. 1–18, 2004.
 F. Peter Guengerich and Q. Cheng, “Orphans in the human
cytochrome P450 superfamily: approaches to discovering
functions and relevance in pharmacology,” Pharmacological
Reviews, vol. 63, no. 3, pp. 684–699, 2011.
 B. E. Daikh, J. M. Lasker, J. L. Raucy, and D. R. Koop, “Regio-
and stereoselective epoxidation of arachidonic acid by human
cytochromes P450 2C8 and 2C9,” Journal of Pharmacology
and Experimental Therapeutics, vol. 271, no. 3, pp. 1427–1433,
 S. Wu, C. R. Moomaw, K. B. Tomer, J. R. Falck, and D.
C. Zeldin, “Molecular cloning and expression of CYP2J2, a
expressed in heart,” The Journal of Biological Chemistry, vol.
271, no. 7, pp. 3460–3468, 1996.
6 International Journal of Vascular Medicine
 A. Gaedigk, D. W. Baker, R. A. Totah et al., “Variability
of CYP2J2 expression in human fetal tissues,” Journal of
Pharmacology and Experimental Therapeutics, vol. 319, no. 2,
pp. 523–532, 2006.
 A. B. Rifkind, C. Lee, T. K. H. Chang, and D. J. Waxman,
“Arachidonic acid metabolism by human cytochrome P450s
2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and
evidence for a role for CYP2C enzymes in arachidonic
acid epoxygenation in human liver microsomes,” Archives of
 R. Mitra, Z. Guo, M. Milani et al., “CYP3A4 mediates growth
of estrogen receptor-positive breast cancer cells in part by
inducing nuclear translocation of phospho-Stat3 through
biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET),”
The Journal of Biological Chemistry, vol. 286, no. 20, pp.
 J. H. Capdevila, A. Karara, D. J. Waxman, M. V. Martin, J.
R. Falck, and F. P. Guenguerich, “Cytochrome P-450 enzyme-
specific control of the regio- and enantiofacial selectivity of
the microsomal arachidonic acid epoxygenase,” The Journal of
Biological Chemistry, vol. 265, no. 19, pp. 10865–10871, 1990.
 D. S. Keeney, C. Skinner, S. Wei, T. Friedberg, and M. R.
Waterman, “A keratinocyte-specific epoxygenase, CYP2B12,
ing a single major epoxyeicosatrienoic acid,” The Journal of
Biological Chemistry, vol. 273, no. 15, pp. 9279–9284, 1998.
binant cytochrome P450 2D18 metabolism of dopamine and
arachidonic acid,” Journal of Pharmacology and Experimental
Therapeutics, vol. 294, no. 3, pp. 1120–1130, 2000.
 M. F. Oleksiak, S. Wu, C. Parker, S. I. Karchner, J. J. Stegeman,
and D. C. Zeldin, “Identification, functional characterization,
and regulation of a new cytochrome P450 subfamily, the
CYP2Ns,” The Journal of Biological Chemistry, vol. 275, no. 4,
pp. 2312–2321, 2000.
 X. Nguyen, M. H. Wang, K. M. Reddy, J. R. Falck, and M.
L. Schwartzman, “Kinetic profile of the rat CYP4A isoforms:
arachidonic acid metabolism and isoform-specific inhibitors,”
American Journal of Physiology, vol. 276, no. 6, part 2, pp.
 J. D. Imig, “Epoxides and soluble epoxide hydrolase in
cardiovascular physiology,” Physiological Reviews, vol. 92, no.
1, pp. 101–130.
 B. T. Larsen, H. Miura, O. A. Hatoum et al., “Epoxye-
icosatrienoic and dihydroxyeicosatrienoic acids dilate human
coronary arterioles via BKCa channels: implications for
soluble epoxide hydrolase inhibition,” American Journal of
Physiology, vol. 290, no. 2, pp. H491–H499, 2006.
 A. A. Spector, X. Fang, G. D. Snyder, and N. L. Weintraub,
“Epoxyeicosatrienoic acids (EETs): metabolism and biochem-
ical function,” Progress in Lipid Research, vol. 43, no. 1, pp. 55–
 J. D. Imig, “Eicosanoid regulation of the renal vasculature,”
American Journal of Physiology, vol. 279, no. 6, pp. F965–F981,
 N. L. Weintraub, X. Fang, T. L. Kaduce, M. VanRollins,
P. Chatterjee, and A. A. Spector, “Epoxide hydrolases reg-
ulate epoxyeicosatrienoic acid incorporation into coronary
endothelial phospholipids,” American Journal of Physiology,
vol. 277, no. 5, part 2, pp. H2098–H2108, 1999.
 D. Zhang, X. Xie, Y. Chen, B. D. Hammock, W. Kong, and
Y. Zhu, “Homocysteine upregulates soluble epoxide hydrolase
in vascular endothelium in vitro and in vivo,” Circulation
Research, vol. 110, no. 6, pp. 808–817.
 M. Revermann, M. Schloss, E. Barbosa-Sicard et al., “Soluble
epoxide hydrolase deficiency attenuates neointima formation
in the femoral cuff model of hyperlipidemic mice,” Arterioscle-
rosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 909–
 L. N. Zhang, J. Vincelette, Y. Cheng et al., “Inhibition of sol-
uble epoxide hydrolase attenuated atherosclerosis, abdominal
aortic aneurysm formation, and dyslipidemia,” Arteriosclero-
sis, Thrombosis, and Vascular Biology, vol. 29, no. 9, pp. 1265–
 C. R. Lee, J. D. Imig, M. L. Edin et al., “Endothelial
expression of human cytochrome P450 epoxygenases lowers
blood pressure and attenuates hypertension-induced renal
injury in mice,” The FASEB Journal, vol. 24, no. 10, pp. 3770–
 P. Luo, H. H. Chang, Y. Zhou et al., “Inhibition or deletion of
soluble epoxide hydrolase prevents hyperglycemia, promotes
insulin secretion, and reduces islet apoptosis,” Journal of
Pharmacology and Experimental Therapeutics, vol. 334, no. 2,
pp. 430–438, 2010.
 B. Fissithaler, R. Popp, L. Kiss et al., “Cytochrome P450 2C is
an EDHF synthasein coronary arteries,” Nature, vol. 401, no.
6752, pp. 493–497, 1999.
 B. Fisslthaler, I. Fleming, and R. Busse, “EDHF: a cytochrome
P450 metabolite in coronary arteries,” Seminars in Perinatol-
ogy, vol. 24, no. 1, pp. 15–19, 2000.
 J. Bystrom, J. A. Wray, M. C. Sugden et al., “Endogenous
epoxygenases are modulators of monocyte/macrophage activ-
ity,” PLoS ONE, vol. 6, no. 10, Article ID e26591, 2011.
 K. Node, Y. Huo, X. Ruan et al., “Anti-inflammatory prop-
erties of cytochrome P450 epoxygenase-derived eicosanoids,”
Science, vol. 285, no. 5431, pp. 1276–1279, 1999.
 K. Nakayama, T. Nitto, T. Inoue, and K. Node, “Expression
of the cytochrome P450 epoxygenase CYP2J2 in human
 M. Spiecker, H. Darius, T. Hankeln et al., “Risk of coro-
nary artery disease associated with polymorphism of the
cytochrome P450 epoxygenase CYP2J2,” Circulation, vol. 110,
no. 15, pp. 2132–2136, 2004.
 U. R. Michaelis, B. Fisslthaler, M. Medhora, D. Harder,
I. Fleming, and R. Busse, “Cytochrome P450 2C9-derived
epoxyeicosatrienoic acids induce angiogenesis via cross-talk
with the epidermal growth factor receptor (EGFR),” The
FASEB Journal, vol. 17, no. 6, pp. 770–772, 2003.
remnant kidney in the 5/6-nephrectomized rat via inhibition
of apoptosis andfibrosis,” Human Gene Therapy. In press.
 Y. Deng, M. L. Edin, K. N. Theken et al., “Endothelial CYP
epoxygenase overexpression and soluble epoxide hydrolase
mice,” The FASEB Journal, vol. 25, no. 2, pp. 703–713, 2011.
 W. Kozak, D. M. Aronoff, O. Boutaud, and A. Kozak, “11,12-
Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin
E2 in rat monocytes stimulated with lipopolysaccharide,”
Experimental Biology and Medicine, vol. 228, no. 7, pp. 786–
 K. Werner, W. R. Schaefer, H. Schweer, W. R. Deppert, U.
Karck, and H. P. Zahradnik, “Characterization and identifi-
cation of cytochrome P450 metabolites of arachidonic acid
released by human peritoneal macrophages obtained from the
International Journal of Vascular Medicine7
pouch of Douglas,” Prostaglandins Leukotrienes and Essential
Fatty Acids, vol. 67, no. 6, pp. 397–404, 2002.
 K. A. Pritchard Jr., R. R. Tota, M. B. Stemerman, and P. Y. K.
Wong, “14,15-Epoxyeicosatrienoic acid promotes endothelial
cell dependent adhesion of human monocytic tumor U937
cells,” Biochemical and Biophysical Research Communications,
vol. 167, no. 1, pp. 137–142, 1990.
 P. F. Pratt, M. Rosolowsky, and W. B. Campbell, “Effects of
epoxyeicosatrienoic acids on polymorphonuclear leukocyte
function,” Life Sciences, vol. 70, no. 21, pp. 2521–2533, 2002.
 C. Morin, M. Sirois, V. Echave, M. M. Gomes, and E.
Rousseau, “EET displays anti-inflammatory effects in TNF-α-
pp. 192–201, 2008.
 K. L. Fife, Y. Liu, K. R. Schmelzer et al., “Inhibition of
soluble epoxide hydrolase does not protect against endotoxin-
mediated hepatic inflammation,” Journal of Pharmacology and
Experimental Therapeutics, vol. 327, no. 3, pp. 707–715, 2008.
 M. S. Hayden and S. Ghosh, “Shared principles in NF-κB
signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008.
 M.S. Hayden and S.Ghosh, “NF-κB, the firstquarter-century:
remarkable progress and outstanding questions,” Genes &
Development, vol. 26, no. 3, pp. 203–234, 2012.
 I. Fleming, U. R. Michaelis, D. Bredenk¨ otter et al.,
(cytochrome P450 2C9) is a functionally significant source
of reactive oxygen species in coronary arteries,” Circulation
Research, vol. 88, no. 1, pp. 44–51, 2001.
 L. Williams, L. Bradley, A. Smith, and B. Foxwell, “Signal
transducer and activator of transcription 3 is the dominant
mediator of the anti-inflammatory effects of IL-10 in human
 J. Berger and D. E. Moller, “The mechanisms of action of
PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435,
 L. A. Cowart, S. Wei, M. H. Hsu et al., “The CYP4A
isoforms hydroxylate epoxyeicosatrienoic acids to form high
affinity peroxisome proliferator-activated receptor ligands,”
The Journal of Biological Chemistry, vol. 277, no. 38, pp.
 J. A. Wray, M. C. Sugden, D. C. Zeldin et al., “The epoxyge-
nases CYP2J2 activates the nuclear receptor PPARα in vitro
and in vivo,” PLoS ONE, vol. 4, no. 10, Article ID e7421, 2009.
 Y. Liu, Y. Zhang, K. Schmelzer et al., “The antiinflammatory
effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic
acids, and soluble epoxide hydrolase,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 102, no. 46, pp. 16747–16752, 2005.
 X. Fang, S. Hu, B. Xu et al., “14,15-Dihydroxyeicosatrienoic
acid activates peroxisome proliferator-activated receptor-α,”
American Journal of Physiology, vol. 290, no. 1, pp. H55–H63,
 J. J. Olearczyk, M. B. Field, I. H. Kim, C. Morisseau, B.
D. Hammock, and J. D. Imig, “Substituted adamantyl-urea
inhibitors of the soluble epoxide hydrolase dilate mesenteric
resistance vessels,” Journal of Pharmacology and Experimental
Therapeutics, vol. 318, no. 3, pp. 1307–1314, 2006.
 P. L. Li and W. B. Campbell, “Epoxyeicosatrienoic acids
activate K+channels in coronary smooth muscle through a
80, no. 6, pp. 877–884, 1997.
 P. Y. K. Wong, K. T. Lin, Y. T. Yan et al., “14(R),15(S)-
epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in
guinea pig mononuclear cell membranes,” Journal of Lipid
Mediators, vol. 6, no. 1–3, pp. 199–208, 1992.
 H. Watanabe, J. Vriens, J. Prenen, G. Droogmans, T. Voets,
and B. Nillus, “Anandamide and arachidonic acid use epoxye-
icosatrienoic acids to activate TRPV4 channels,” Nature, vol.
424, no. 6947, pp. 434–438, 2003.
 S. Earley, T. J. Heppner, M. T. Nelson, and J. E. Brayden,
receptors and BKCa channels,” Circulation Research, vol. 97,
no. 12, pp. 1270–1279, 2005.
 J. Vriens, G. Owsianik, B. Fisslthaler et al., “Modulation of the
Ca2+permeable cation channel TRPV4 by cytochrome P450
epoxygenases in vascular endothelium,” Circulation Research,
vol. 97, no. 9, pp. 908–915, 2005.
 R. L. Baylie and J. E. Brayden, “TRPV channels and vascular
function,” Acta Physiologica, vol. 203, no. 1, pp. 99–116.
 M. W. Buczynski, D. S. Dumlao, and E. A. Dennis, “An
integrated omics analysis of eicosanoid biology,” Journal of
Lipid Research, vol. 50, no. 6, pp. 1015–1038, 2009.
 K. N. Theken, R. N. Schuck, M. L. Edin et al., “Evaluation
of cytochrome P450-derived eicosanoids in humans with
stable atherosclerotic cardiovascular disease,” Atherosclerosis,
vol. 222, no. 2, pp. 530–536.
 C. Morin, M. Sirois, V. Echave, E. Rizcallah, and E. Rousseau,
“Relaxing effects of 17(18)-EpETE on arterial and airway
smooth muscles in human lung,” American Journal of Physi-
ology, vol. 296, no. 1, pp. L130–L139, 2009.